Single-Agent Oral Vinorelbine as First-Line Chemotherapy for Endocrine-Pretreated Breast Cancer With Bone Metastases and No Visceral Involvement: NORBREAST-228 Phase II Study. [electronic resource]
Producer: 20190319Description: e41-e47 p. digitalISSN:- 1938-0666
- Administration, Oral
- Adult
- Aged
- Antineoplastic Agents, Hormonal -- therapeutic use
- Antineoplastic Agents, Phytogenic -- therapeutic use
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Bone Neoplasms -- drug therapy
- Breast -- pathology
- Breast Neoplasms -- drug therapy
- Chemotherapy-Induced Febrile Neutropenia -- epidemiology
- Disease Progression
- Fatigue -- chemically induced
- Female
- Humans
- Middle Aged
- Progression-Free Survival
- Receptors, Estrogen -- metabolism
- Receptors, Progesterone -- metabolism
- Treatment Outcome
- Vinorelbine -- therapeutic use
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.